6th Global Gastroenterologists Meeting 2016
Holiday Inn Birmingham City CentreBirmingham, UK Visit the Venue to read more
Conference Series LLC, the World Class Open Access Publisher and Scientific Event Organizer is delighted to host “6th Global Gastroenterologists Meeting” during August 11-12, 2016 at Birmingham, UK. This gastrointestinal conference highlights the theme “Recent advancements and therapeutic techniques in the field of gastroenterology”. For more details please visit conference series.
Conference Series LLC organizes 300+ International Conferences every year across USA, Europe & Asia with support from 1000 more scientific Societies and publishes 400+ Open Access Journals which contains over 30000 eminent personalities, reputed scientists as editorial board members.
Gastro 2016 mainly focuses on the latest diagnostic and therapeutic techniques for gastric diseases. This gastro conference discusses the latest research outcomes and technological advancements in the field and brings together leading gastroenterologists, surgeons, physicians, research scholars, students along with industrial and pharma professionals to exchange share their views on critical aspects of gastroenterology research. This gastroenterology conference brings together Presidents and Eminent Personalities to explore opportunities on emerging platforms in the field of gastrointestinal therapeutics. With members from around the world focused on learning about latest diagnostic and treatment procedures of various gastrointestinal diseases and all the related aspects of gastrointestinal diseases this is your best opportunity to reach the largest assemblage of participants from the entire world. From the workshop and speech in this gastroenterology conference from the eminent people of gastroenterology, you can update your knowledge about current situation of gastroenterology and receive name and recognition at this 2-day event. Gastro conference will help to provide platform to share ideas. World-renowned speakers with their ultimate talks on the most recent techniques, tactics, and the avant garde technologies in gastrointestinal therapeutics are the hallmarks of this gastroenterology conference.
Gastrointestinal Carcinogenesis and Therapeutics
Gastrointestinal Carcinogenesis as a group are the second most common cancers diagnosed in both men and women. Of all the GI cancers, colorectal cancer is the most common one amongst newly diagnosed GI cancers and pancreatic ductal adenocarcinoma is the most fatal one due to lack of early diagnosis and limited success of systemic therapeutics increased research activities towards development of novel therapeutics. Remarkable progress has been made in pathogenesis, biology, and molecular genetics of Gastric surgery.
Gastro cancer is managed by therapeutics with multi-disciplinary approach, involving several medical, surgical, radiological, pathological, gastroenterologists, hepatologists, and scientists. Key innovations and novel therapies have led to improved understanding of pathogenesis and achieve earlier detection, and advances in the management of Gastric banding and gastroplasty surgery. The most prevalent of gastrointestinal cancers is colorectal cancer in the Western world and gastric cancer in the Eastern world. Colorectal cancer is the third most common cancer in the world, with nearly 1.4 million new cases diagnosed in 2012 and Gastric cancer accounts for approximately 9,52,000 deaths each year worldwide. There are about 900 medical universities working on gastrointestinal cancers worldwide. This gastroenterology conference will provide a common place to be together and share their gastroenterology researches.
Inflammatory bowel disease Research vs Treatment / Management
The care of a patient with inflammatory bowel disease Research can be either medical or surgical in nature or, in many patients, a combination of both the treatment and Management of IBDR. The goals of therapy are the achievement of remission and the prevention of disease flares maintenance.
The concept of deep mucosal healing, particularly in Crohn’s disease, is becoming increasingly advocated. There are several studies, primarily involving anti-TNF agents and occasionally immune modifiers; that have shown that the elimination of inflammation as demonstrated by endoscopic and histologic criteria results in a decrease in the rate of surgery, the use of corticosteroids, and the rate of hospitalization.
The medical approach for patients with symptomatic care and mucosal healing following a stepwise approach to medication, with escalation of the medical regimen until a response is achieved.
Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators, Pharmacotherapy, Tumor necrosis factor inhibitors Monoclonal antibodies, UC is surgically curable. Crohn's disease and ulcerative colitis are the principal types of inflammatory bowel disease. In the United States, it is currently estimated that about 1-1.3 million people suffer from IBD. According to the Crohn's & Colitis Foundation of America, about 1.4 million Americans have Crohn’s disease or gastric ulcer. Of those, about 700,000 have Crohn’s. Gastro conference has a special eye to deal with Crohn’s disease.
Gastrointestinal Bleeding- Treatment and Management
Acute upper gastrointestinal bleeding is the most common gastroenterological emergency and has a considerable morbidity and mortality. Management strategies have changed dramatically over recent decades due to the introduction of acid suppressive therapy histamine-2 receptor antagonists and especially proton pump inhibitors and endoscopic therapy.
Patients with Gastrointestinal Bleeding can present with various symptoms such as hematemesis, hematochezia, melena, or progressive anemia. Immediate evaluation and appropriate treatment is of major importance in these patients. Laparoscopic gastric surgery is generally safe in the setting of gastrointestinal bleeding, as long as the patient has been sufficiently resuscitated before the procedure. Treatment and Management with scopy examinations summarized only one endoscopic complication perforation of a diverticulum was reported. A nasogastric tube can be used to administer this solution if the patient is unable to tolerate it by mouth. Those patients who have bled and apparently stopped, it is reasonable to administer the prep and perform the examination on an elective or semi elective basis. For those patients with continued hematochezia, the examination should be performed as soon as possible. GI bleeding results in 250,000 to 300,000 hospitalizations and 15,000 to 30,000 deaths per year in the United States. More than $2.5 billion is spent annually for inpatient care of this problem.
Pancreatic diseases and Treatment
Pancreatic diseases are inflammation of the pancreas it also synthesizes and secretes insulin and glucon. Pancreatic or pancreatitis disease may be caused by gallstones, chronic alcohol use, trauma, medications, infections, tumors, and genetic abnormalities that is often severe and constant over several days, and may be accompanied by fever, nausea, vomiting, tachycardia and abdominal swelling.
Treatment for Pancreatitis is diagnosed preliminarily by physical exam and the levels of amylase and lipase in the blood. Other tests it may be done to detect gallstones or to identify the damaged pancreas and other blood tests may need to be done.
Gallstones may be removed using therapeutic endoscopic retrograde cholangiopancreatography (ERCP). This year, an estimated 48,960 adults (24,840 men and 24,120 women) in the United States will be diagnosed with pancreatic cancer. It is estimated that 40,560 deaths (20,710 men and 19,850 women) from this disease will occur this year. Pancreatic cancer is the eighth most common cancer in women and the fourth leading cause of cancer death in men and women.
Emerging therapies for Viral Hepatitis and Liver Fibrosis
Emerging therapies to treat viral hepatitis C virus (HCV) are evolving rapidly. With the introduction of interferon‐α monotherapy based on triple therapies with pegylated interferon‐α and ribavirin , the chances of curing patients infected with HCV genotype 1 have improved from <10% to approximately 70%.
Liver fibrosis occurs as a result of a wide range of injurious processes and in its end-stage results in cirrhosis. Indeed, liver fibrosis and cirrhosis represent a major worldwide healthcare burden. Recent progress in liver transplantation, the management of portal hypertension and the treatment of chronic viral hepatitis have had an important impact.
However, these approaches are not without their limitations – in particular, issues regarding organ availability for transplantation and serve to highlight the urgent requirement to influence pharmacologically the underlying fibrotic process in many patients. Gastro conference will be having a special session on Viral Hepatitis.
Treatment for Functional GI disorders
Functional Gastrointestinal disorders remain a common problem in the pediatric age group, with pediatric gastro oncology. These conditions were first recognized in 1958 when he coined the earlier term ‘recurrent abdominal pain’ (RAP) for a group of children with recurrent or persistent abdominal pain that interfered with functional daily living and had no evident organic etiology.
This review focuses on dietary, pharmacologic, cognitive behavioral and complementary medical treatment. IBS is most common in adults along with gastroenteritis and most of the treatments in the adult population have been geared toward treating that disorder.
Medications used to treat depression, anxiety, and seizures have become increasingly attractive agents for use in Functional Gastro Intestinal Disorders because they act upon the central and peripheral nervous system to modulate mood, visceral, and neuropathic pain, as well as autonomic function, in part, through anticholinergic effects.
Antidepressants such as tricyclic antidepressants (TCAs), serotonin reuptake inhibitors (SSRIs), and monoamine uptake inhibitors improve symptoms of IBS in adults. Antidepressants act by decreasing pain perception, improving mood and disturbed sleep patterns, and perhaps regulating motility. Of all the functional GI disorders, irritable bowel syndrome (IBS) is the most studied and among the most common. IBS is highly prevalent, affecting between 10–15% of the U.S. population. A Significant proportion – 35% to 40% of individuals who report IBS in the community are male and 60% to 65% of individuals who report IBS in the community are female.
Group registrations not allowed
Accompanying persons not allowed
We don’t accept Online Abstracts
Birmingham City Centre
Birmingham, B5 4EW
Drop us an email for Program enquiry.
Sponsors / Exhibiting / Advertising.
Drop us an email for Program enquiry.
Sponsors / Exhibiting / Advertising.